ATOMOXETINA MYLAN 60mg capsules medication leaflet

N06BA09 atomoxetine • Nervous system | Psychostimulants, agents used for adhd and nootropics | Centrally acting sympathomimetics

Atomoxetine is a selective norepinephrine reuptake inhibitor (sNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, cognitive disengagement syndrome (CDS).
It may be used alone or along with stimulant medication.
It enhances the executive functions of self-motivation, sustained attention, inhibition, working memory, reaction time, and emotional self-regulation.
Use of atomoxetine is only recommended for those who are at least six years old.
It is taken orally. The effectiveness of atomoxetine is comparable to the commonly prescribed stimulant medication methylphenidate.

Atomoxetine alleviates ADHD symptoms through norepinephrine reuptake inhibition and by indirectly increasing dopamine in the prefrontal cortex, sharing 70-80% of the brain regions with stimulants in their produced effects.

Unlike α2-adrenergic receptor agonists such as guanfacine and clonidine, atomoxetine's use can be abruptly stopped without significant withdrawal symptoms being observed.

General data about ATOMOXETINA MYLAN 60mg

Substance: atomoxetine

Date of last drug list: 01-08-2018

Commercial code: W64343003

Concentration: 60mg

Pharmaceutical form: capsules

Quantity: 56

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: MC DERMOTT LABORATORIES LTD. TRADING AS GERARD LAB - IRLANDA

Holder: MYLAN S.A.S. - FRANTA

Number: 10532/2018/03

Shelf life: 2 years

Pharmaceutical forms available for atomoxetine

Concentrations available for atomoxetine

100mg, 10mg, 18mg, 25mg, 40mg, 4mg/ml, 60mg, 80mg

Other substances similar to atomoxetine